Electronic Journal of Pharmacology & Therapy, 7: 1-4 (2014)
1. Ormeloxifene; medical management of dysfunctional uterine bleeding
Kaur, S., Kaur, S., Mittal, R., Mittal N. and Shruti,
Department of Obst & Gynae, M. M. Medical College Kumarhatti, Solan ( HP ).
E mail: drsatwantkaur@yahoo.com, Cell: 073075 85558
Abstract: To evaluate the efficacy of Ormeloxifene in DUB. Medical management of DUB is a challenging task and many drugs are available for this condition but show lack of consensus for medical treatment. Ormeloxifene mediates its effects by high affinity interaction with ER, antagonizing the effect of estrogen on uterine and breast tissue and agonizing the effect on vagina, bone, cardiovascular system. So it is suitable for medical management of DUB. Sixty five women aged between 30 to 50 were recruited for the study whom chief complaint was heavy menstrual flow. Ormeloxifene 60 mg was given orally twice in a week for first 12 weeks followed by once in a week for next 12 weeks. Menstrual blood loss measurements using subjective assessment of amount of flow, blood hemoglobin and endometrial thickness were the main measurements to evaluate the efficacy of therapy. Statistical analysis was done using a paired ‘t‘ test and ‘z‘ test. The difference in mean heamoglobin concentration of 1.31gm/dl between pretreatment and post-treatment levels was also statisticallysignificant (P<0.001). 87.05% showed a reduction in endometrial thickness as assessed by transvaginalsonography. 8.2% women needed hysterectomy. Ormeloxifene is an effective drug therapy in medical management of DUB.
Key words: Ormeloxifene , Menorrhagia
Electronic Journal of Pharmacology & Therapy, 7: 5-7 (2009)
2. Extensive utilization of cell culture based vaccines in the modern scenario
Jainth, S. and Gupta, M.
Department of Scientific Research, Mahatma Jyoti Rao Phoole University, Jaipur (Rajasthan).
E. mail: rubyharshita@gmail.com
Abstract: Hopes of growing poliovirus in the lab without the use of live animals drove many of the researchers in the 1930s and 1940s. Cell cultures involve growing cells in a culture dish, often with a supportive growth medium like collagen. They offer a level of control that was unavailable using live animals, and can also support large-scale virus production. (For more about cell cultures and cell lines, as well as cell lines made using human cells, see our article “Human Cell Strains in Vaccine Development.”) Early efforts to grow poliovirus in culture, however, repeatedly ended in failure. In 1936, Albert Sabin and Peter Olitsky at the Rockefeller Institute successfully grew poliovirus in a culture of brain tissue from a human embryo. The virus grew quickly, which was promising, but Sabin and Olitsky were concerned about using this as starting material for a vaccine, fearing nervous system damage for vaccine recipients. They tried to grow poliovirus in cultures using tissue that had been taken from other sources, but were unsuccessful. Today, many different animal cell strains are available for use in scientific research and development. Several vaccines currently available in the United States were developed using the Vero cell line, started from African green monkey kidney cells: Rotavirus vaccines (Rotarix/GlaxoSmithKline, RotaTeq/Merck), Polio (IPOL/Sanofi Pasteur). Smallpox (ACAM2000/Sanofi Pasteur – Used only for selected military personnel). Japanese encephalitis (Ixiaro/Intercell – Used only for those traveling to areas with known outbreaks of disease). Future U.S. vaccines may use other animal cell strains, including the Madin Darby Canine Kidney (MDCK) line, which was started in 1958 with kidney cells from a cocker spaniel. (Some European vaccines are already made using MDCK.)
Key words: Cell cultures based vaccines
|
